Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy CytomX Therapeutics (CTMX) stocks

Learn how to easily invest in CytomX Therapeutics stocks.

CytomX Therapeutics is a biotechnology business based in the US. CytomX Therapeutics stocks (CTMX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.08 – a decrease of 3.45% over the previous week. CytomX Therapeutics employs 116 staff and has a trailing 12-month revenue of around $67.6 million.

How to buy CytomX Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – CTMX. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Promoted for Beginners

National Bank Direct Brokerage

  • Commission-free trading
  • Several account types available
  • Access to array of research tools

Promoted for Low Fees

CIBC Investor's Edge

  • Easy to use platform
  • Low fees
  • Student and young investor discounts

Best for Lowest Commissions

Finder Award

Interactive Brokers

  • Access to international stock exchanges
  • Low margin rates
  • Powerful research tools

CytomX Therapeutics stock price (NASDAQ:CTMX)

Use our graph to track the performance of CTMX stocks over time.

CytomX Therapeutics shares at a glance

Information last updated 2023-05-26.
Latest market close$1.68
52-week range$1.17 - $3.02
50-day moving average $1.69
200-day moving average $1.78
Wall St. target price$2.52
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.96

Buy CytomX Therapeutics stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 5 of 5
Name Product Finder Rating Available Asset Types Stock Trading Fee Account Fee Signup Offer Table description
CIBC Investor's Edge
Finder Rating:
3.8 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs
$0 if conditions met, or $100
An easy-to-use platform with access to a variety of tools to help you trade with confidence.
Interactive Brokers
Finder Rating:
4.3 / 5
Stocks, Bonds, Options, ETFs, Currencies, Futures
min $1.00, max 0.5%
Winner for Best Overall Broker in the Finder Stock Trading Platform Awards.
National Bank Direct Brokerage
Finder Rating:
4.2 / 5
Stocks, Bonds, Options, Mutual Funds, GICs
$0 if conditions met, or $100
Get $0 commission on all transactions with promo code: finder
Finder Rating:
4.3 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95 - $9.95
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio to take out some of the guesswork.
Qtrade Direct Investing
Finder Rating:
3.7 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Get up to $150 sign-up bonus. Use promo code BONUS150. Conditions apply. Ends June 30, 2023.
Low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options.

Is it a good time to buy CytomX Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

CytomX Therapeutics price performance over time

Historical closes compared with the close of $1.68 from 2023-06-01

1 week (2023-05-26) -3.45%
1 month (2023-05-02) 1.82%
3 months (2023-03-02) -21.86%
6 months (2022-12-02) -1.75%
1 year (2022-06-01) 8.39%
2 years (2021-05-29) N/A
3 years (2020-06-02) 8.12
5 years (2018-06-01) 25.53
[/expander_content] [/expander]

CytomX Therapeutics financials

Revenue TTM $67.6 million
Gross profit TTM $53.2 million
Return on assets TTM -15.81%
Return on equity TTM -5475.03%
Profit margin -104.47%
Book value $-1.31
Market capitalisation $113.8 million

TTM: trailing 12 months

CytomX Therapeutics share dividends

We're not expecting CytomX Therapeutics to pay a dividend over the next 12 months.

CytomX Therapeutics share price volatility

Over the last 12 months, CytomX Therapeutics's shares have ranged in value from as little as $1.17 up to $3.02. A popular way to gauge a stock's volatility is its "beta".

CTMX.US volatility(beta: 0.65)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CytomX Therapeutics's is 0.6527. This would suggest that CytomX Therapeutics's shares are less volatile than average (for this exchange).

CytomX Therapeutics overview

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; CX-2051, a conditionally activated ADC that targets epithelial cell adhesion molecule-expressing epithelial cancers; and CX-801, a dually masked, conditionally activated version of Interferon alpha-2b therapy for a range of tumor types. The company also develops BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I/II clinical trials for the treatment of solid tumors; and CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. It has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc. , Bristol-Myers Squibb Company, Astellas Pharma Inc.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site